Literature DB >> 22959314

Tranexamic acid-bevacizumab synergy in HHT patients presenting pulmonary arteriovenous malformations.

Alexis Lacout1, Pierre Yves Marcy, Mostafa El Hajjam, Pascal Lacombe.   

Abstract

Bevacizumab and tranexamic acid have shown efficacy in the treatment of epistaxis and liver involvement of HHT patients. We suggest therapeutic association of bevacizumab and tranexamic acid should be further evaluated for the prevention and treatment of early lung involvement in HHT.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22959314     DOI： 10.1016/j.mehy.2012.07.031

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN： 0306-9877            Impact factor:   1.538


  1 in total

1.  Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia.

Authors:  Mary E Sehl; Theresa M Gruber; Justin P McWilliams; Victor J Marder
Journal:  Am J Hematol       Date:  2015-05-10       Impact factor: 10.047
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.